In fact, Egln3H196A evoked increases in both Klf5 and Oct4 that we speculate may be due to potential dominant-negative effects of Egln3H196A expression within glioma upon other signaling pathways (e.g. Egln1). Here, POU5F1 is linked to central nervous system cancer.